MA40846A - Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques - Google Patents

Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques

Info

Publication number
MA40846A
MA40846A MA040846A MA40846A MA40846A MA 40846 A MA40846 A MA 40846A MA 040846 A MA040846 A MA 040846A MA 40846 A MA40846 A MA 40846A MA 40846 A MA40846 A MA 40846A
Authority
MA
Morocco
Prior art keywords
micellizing
compositions
self
treatment
well
Prior art date
Application number
MA040846A
Other languages
English (en)
Inventor
Ahmed Abd Almalik Ahmed Mohammed Daak
Glynis Daniel-Archibald
Miguel Lopez-Toledano
Frederick D Sancilio
Thorsteinn Thorsteinsson
Original Assignee
Sancilio & Company Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54347886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40846(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sancilio & Company Inc filed Critical Sancilio & Company Inc
Publication of MA40846A publication Critical patent/MA40846A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MA040846A 2014-10-10 2015-10-08 Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques MA40846A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462062643P 2014-10-10 2014-10-10
US201462062646P 2014-10-10 2014-10-10
US201462062634P 2014-10-10 2014-10-10
US201462062652P 2014-10-10 2014-10-10
US201462062638P 2014-10-10 2014-10-10
US201462062651P 2014-10-10 2014-10-10

Publications (1)

Publication Number Publication Date
MA40846A true MA40846A (fr) 2017-09-05

Family

ID=54347886

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040846A MA40846A (fr) 2014-10-10 2015-10-08 Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques

Country Status (8)

Country Link
EP (1) EP3212236A1 (fr)
BR (1) BR112017007428A2 (fr)
CA (1) CA2963952C (fr)
CL (1) CL2017000867A1 (fr)
MA (1) MA40846A (fr)
MX (2) MX2017004324A (fr)
WO (1) WO2016057915A1 (fr)
ZA (1) ZA201702385B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692973A (zh) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
CA3023648C (fr) * 2016-05-10 2023-11-28 Shenzhen Hightide Biopharmaceutical, Ltd. Composition, et application et preparation pharmaceutique de cette derniere
AU2017301077B2 (en) 2016-08-12 2022-07-07 Pharmako Biotechnologies Pty Limited Omega-3 compositions and methods relating thereto
ES3066545T3 (en) * 2017-02-07 2026-05-13 Fresenius Kabi Deutschland Gmbh Long-term efficacy of liver disease treatment with epa and dha
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
IT201900007202A1 (it) * 2019-05-24 2020-11-24 Pavia Farm S R L Composizione a base di vitamine liposolubili ad elevato assorbimento enterico
EP4014758A4 (fr) 2019-08-13 2023-08-16 Team Foods Colombia S.A. Composition lipidique qui comprend des antioxydants et des polyphénols naturels comme alternative non pharmacologique pour le traitement et la prévention de la nafld
CN115737555B (zh) * 2022-05-20 2024-06-21 深圳海王医药科技研究院有限公司 一种千金藤素自微乳组合物、制剂及其制备方法
CN117730823A (zh) * 2022-09-20 2024-03-22 上海中医药大学 原发性硬化性胆管炎合并炎症性肠病的造模方法
WO2026030644A1 (fr) * 2024-07-31 2026-02-05 Caper Labs, Inc. Thérapie à l'acide arachidonique pour le traitement de la neutropénie
CN121867416B (zh) * 2026-03-19 2026-07-03 飞鹤(阿鲁科尔沁旗)乳品有限公司 一种营养组合物的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3181131A1 (fr) * 2009-05-22 2017-06-21 Mochida Pharmaceutical Co., Ltd. Composition auto-émulsifiante de 3 acides gras
WO2012032414A2 (fr) * 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprenant un mélange d'huile constituée d'acides gras, un tensioactif et une statine
TW201343203A (zh) * 2011-12-22 2013-11-01 普諾華生物製藥諾治股份有限公司 含有ω-3脂肪酸之經明膠/藻酸鹽延緩釋放型膠囊,其製法及用途
IN2014DN08449A (fr) * 2012-03-30 2015-05-08 Sancilio & Company Inc

Also Published As

Publication number Publication date
MX2020002238A (es) 2020-07-13
ZA201702385B (en) 2020-12-23
WO2016057915A1 (fr) 2016-04-14
MX2017004324A (es) 2017-07-04
CA2963952C (fr) 2023-10-17
EP3212236A1 (fr) 2017-09-06
CL2017000867A1 (es) 2017-11-03
BR112017007428A2 (pt) 2017-12-19
CA2963952A1 (fr) 2016-04-14

Similar Documents

Publication Publication Date Title
EP2981551A4 (fr) Méthodes et compositions pour le traitement de la maladie de pompe
IL249821A0 (en) Omega-3 fatty acid ester compositions
EP2822923A4 (fr) Préparation d'acides carboxyliques alpha,bêta-insaturés et de leurs esters
MY165048A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
ZA201702385B (en) Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
EP2836226A4 (fr) Compositions et méthodes pour le traitement d'hémoglobinopathies
HUE065662T2 (hu) Készítmények és eljárások betegségek kezelésére
HUE051476T2 (hu) Kannabidiolsav alkalmazása az epilepszia kezelésében
PL2444081T3 (pl) Kompozycja do leczenia chorób zapalnych, zawierająca kwas bosweliowy i kannabidiol
EP3661600A4 (fr) Analogues d'acides gras et leur utilisation dans le traitement des états liés au syndrome métabolique
EP2819687A4 (fr) Compositions et méthodes de traitement d'une maladie vasculaire périphérique
CY1123942T1 (el) Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
IL233639B (en) Compositions and methods for the treatment of hepatic diseases and disorders
HUE046239T2 (hu) Zsírsav keverékek gyulladásos megbetegedések kezelésében való alkalmazásra
EP2947141A4 (fr) Micro-organismes produisant de l'acide docosahexaénoïque et leur utilisation
IL247529A0 (en) Lipoic acid choline ester compositions and methods of use
FR3030231B1 (fr) Utilisation d'un ester d'acide gras pour matifier la peau et composition comprenant cet ester
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
MX2017001293A (es) Metodos y composiciones para diagnosticar y tratar trastornos inflamatorios del intestino.
EP3316874A4 (fr) Compositions topiques et injectables de résiquimod pour le traitement d'affections cutanées néoplasiques
EP3318261A4 (fr) Utilisation de l'acide zolédronique pour préparer un médicament pour le traitement de la stéatose hépatique
EP2964750A4 (fr) Méthodes et compositions utilisables en vue du traitement et/ou de la prévention du diabète de type 1